{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:20:15Z","timestamp":1772760015900,"version":"3.50.1"},"reference-count":83,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1586\/17474086.2013.837279","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T07:28:47Z","timestamp":1380698927000},"page":"563-574","source":"Crossref","is-referenced-by-count":22,"title":["Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors"],"prefix":"10.1586","volume":"6","author":[{"given":"Gabriele","family":"Gugliotta","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Fogli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology \u201cL. e A. Seragn\u00f2li\u201d,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.07.007"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.245"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"issue":"10","key":"e_1_3_3_11_1","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent P","year":"2011","unstructured":"Valent P. Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 96(10), 1395\u20131397 (2011).","journal-title":"Haematologica"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003637282"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1481-7"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws101"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"issue":"33","key":"e_1_3_3_18_1","article-title":"Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation","volume":"31","author":"Vidiri A","year":"2012","unstructured":"Vidiri A, Pace A, Fabi A et al. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J. Exp. Clin. Can. Res. 31, 33 (2012).","journal-title":"J. Exp. Clin. Can. Res"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053058"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294330"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.983"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.524"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.20.2269"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041601"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bmj.39201.463819.2C","article-title":"Multimorbidity's many challenges","volume":"334","author":"Fortin M","unstructured":"Fortin M, Soubhi H, Hudon C, Bayliss EA, Van Den Akker M. Multimorbidity's many challenges. BMJ 334(7602), 1016\u20131017 (2007).","journal-title":"BMJ"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318074d3c1"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00306-5"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:BEGE.0000017871.87431.2a"},{"issue":"1","key":"e_1_3_3_29_1","first-page":"53","article-title":"Ambulatory care groups: a categorization of diagnoses for research and management","volume":"26","author":"Starfield B","year":"1991","unstructured":"Starfield B, Weiner J, Mumford L, Steinwachs D. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv. Res. 26(1), 53\u201374 (1991).","journal-title":"Health Serv. Res"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/62.3.296"},{"issue":"9","key":"e_1_3_3_31_1","first-page":"1125","article-title":"Patient reported outcome measures: a model-based classification system for research and clinical practice","volume":"17","author":"Valderas JM","year":"2008","unstructured":"Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. QualLife Res. 17(9), 1125\u20131135 (2008).","journal-title":"QualLife Res"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/59.3.M255"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm136"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2007.05.002"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0307-0"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1886"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1233"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1209"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.6.716"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23330"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324228"},{"issue":"21","key":"e_1_3_3_42_1","article-title":"Impact of Comorbidity In Event-Free Survival, Toxicity and Adherence to Treatment In Chronic Myeloid Leukemia Patients Treated with Imatinib","volume":"116","author":"Fogliatto L","year":"2010","unstructured":"Fogliatto L, Capra M, Schaan M et al. Impact of Comorbidity In Event-Free Survival, Toxicity and Adherence to Treatment In Chronic Myeloid Leukemia Patients Treated with Imatinib. ASH Annual Meeting Abstracts 116(21), 2296 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"e_1_3_3_43_1","article-title":"Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival","volume":"118","author":"Breccia M","year":"2011","unstructured":"Breccia M, Luciano L, Latagliata R et al. Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. ASH Annual Meeting Abstracts 118(21), 2751 (2011).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.041251"},{"issue":"21","key":"e_1_3_3_45_1","first-page":"3421","article-title":"Safety and efficacy of dasatinib (DAS) versus imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia In Chronic Phase (CML-CP): analysis of the DASISION trial","volume":"116","author":"Khoury HJ","year":"2010","unstructured":"Khoury HJ, Cortes JE, Kantarjian H et al. Safety and efficacy of dasatinib (DAS) versus imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia In Chronic Phase (CML-CP): analysis of the DASISION trial. ASH Annual Meeting Abstracts 116(21), 3421 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"e_1_3_3_46_1","first-page":"2286","article-title":"Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in Chronic Phase (CML-CP): analysis of the DASISION trial","volume":"116","author":"Saglio G","year":"2010","unstructured":"Saglio G, Hochhaus A, Cortes JE et al. Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in Chronic Phase (CML-CP): analysis of the DASISION trial. ASH Annual Meeting Abstracts 116(21), 2286 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.06.001"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.215"},{"issue":"3","key":"e_1_3_3_49_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"Cortes JE","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. 28(3), 424\u2013430 (2010).","journal-title":"J. Clin"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070144"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0107-13a"},{"issue":"2","key":"e_1_3_3_52_1","first-page":"146","article-title":"Clinical and laboratory studies of expression of cyclin A in leukemia cells","volume":"11","author":"Yu H","year":"2003","unstructured":"Yu H, Xie YH, Fan HH, Zheng B, Xie Y. Clinical and laboratory studies of expression of cyclin A in leukemia cells. Zhongguo shi yan xue ye xue za zhi 11(2), 146\u2013152 (2003).","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"issue":"34","key":"e_1_3_3_53_1","article-title":"Understanding the attitudes of the elderly towards enrolment into cancer clinical trials","volume":"6","author":"Townsley CA","year":"2006","unstructured":"Townsley CA, Chan KK, Pond GR, Marquez C, Siu LL, Straus SE. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 6, 34 (2006).","journal-title":"BMC Cancer"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_3_3_57_1","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","author":"Latagliata R","year":"2012","unstructured":"Latagliata R, Breccia M, Fava C et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol. Oncol.(2012).","journal-title":"Hematol. Oncol"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/153.7.666"},{"key":"e_1_3_3_62_1","doi-asserted-by":"crossref","unstructured":"Selvin E Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey 1999\u20132000. Circulation 110(6) 738\u2013743 (2004).","DOI":"10.1161\/01.CIR.0000137913.26087.F0"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.174526"},{"issue":"3","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jacc.2011.10.860","article-title":"2012 ACCF\/AHA\/ACR\/SCAI\/SIR\/STS\/SVM\/SVN\/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease)","volume":"59","author":"Creager MA","year":"2012","unstructured":"Creager MA, Belkin M, Bluth EI et al. 2012 ACCF\/AHA\/ACR\/SCAI\/SIR\/STS\/SVM\/SVN\/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J. Am. Coll. Cardiol. 59(3), 294\u2013357 (2012).","journal-title":"J. Am. Coll. Cardiol"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.70"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl228"},{"key":"e_1_3_3_67_1","article-title":"The peripheral arterial disease study (PERART\/ARTPER): prevalence and risk factors in the general population","volume":"38","author":"Alzamora MT","year":"2010","unstructured":"Alzamora MT, Fores R, Baena-Diez JM et al. The peripheral arterial disease study (PERART\/ARTPER): prevalence and risk factors in the general population. BMC10, 38 (2010).","journal-title":"BMC10"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.69"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12096"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"issue":"21","key":"e_1_3_3_72_1","first-page":"3430","article-title":"Efficacy and safety of nilotinib in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes in the ENESTnd trial","volume":"116","author":"Saglio G","year":"2010","unstructured":"Saglio G, Larson RA, Hughes TP et al. Efficacy and safety of nilotinib in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes in the ENESTnd trial. ASH Annual Meeting Abstracts 116(21), 3430 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.217"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6910com"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26249"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_3_3_78_1","article-title":"Postnatal aversive experience impairs sensitivity to natural rewards and increases susceptibility to negative events in adult life","author":"Ventura R","year":"2012","unstructured":"Ventura R, Coccurello R, Andolina D et al. Postnatal aversive experience impairs sensitivity to natural rewards and increases susceptibility to negative events in adult life. Cereb. Cortex (2012).","journal-title":"Cereb. Cortex"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010496"},{"issue":"3","key":"e_1_3_3_80_1","first-page":"291","article-title":"Tyrosine kinase inhibitors and acute pancreatitis","volume":"11","author":"Pezzilli R","year":"2010","unstructured":"Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP 11(3), 291\u2013293 (2010).","journal-title":"JOP"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.778406"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.08.002"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.04.002"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-12-200912150-00005"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2441"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(92)90005-N"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474086.2013.837279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:42:02Z","timestamp":1772757722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474086.2013.837279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1586\/17474086.2013.837279"],"URL":"https:\/\/doi.org\/10.1586\/17474086.2013.837279","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}